Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
H-89 and the PKA Branch of Wnt Osteogenesis
2026-11-22
The cited study connects Wnt signaling to bone formation through a time-dependent Ca2+–PKA–GFAT1 pathway, sustained β-catenin activity, O-GlcNAcylation, and PDK1-dependent aerobic glycolysis. H-89 is best interpreted as a probe of the PKA-linked branch rather than as independent evidence that PKA alone controls osteogenesis.
Endogenous Promoters and Rabbit Pharming Yield
2026-11-21
A 2025 study tested whether placing a reporter gene at the rabbit CSN2 milk-protein locus could improve recombinant protein output. Its 15–20 g/L result in two homozygous animals is striking, but the evidence remains a reporter-based proof of concept rather than validation of therapeutic-product performance.
CCR7–Notch1 Crosstalk in Mammary Cancer Stemness
2026-11-20
A study of MMTV-PyMT mammary tumor cells examined whether CCR7 signaling regulates cancer stem-like behavior through Notch1. Its findings support functional crosstalk involving Notch1 activation and Hes1 expression, while the mouse model, pharmacologic specificity and correlative human analysis limit direct clinical interpretation.
Alarelin, PLGA, and Pikeperch Sperm Quality
2026-11-20
A controlled study in male pikeperch found that PLGA-mediated alarelin treatment was associated chiefly with later differences in sperm motility and testosterone, not sperm quantity. The findings support a sustained-release mechanism as a plausible explanation, but they do not yet establish improved fertilisation, prolonged reproductive performance, or equivalence between a catalog material and the tested formulation.
Why Locus Choice Matters in Rabbit Pharming
2026-11-19
A mechanistic reading of evidence that endogenous milk-protein regulatory architecture can raise recombinant-protein output in rabbits, while separating promoter effects from gene dosage, protein-specific behavior, and broader manufacturing claims.
When Context Changes the Meaning of a Yield
2026-11-19
A rabbit pharming study illustrates why a large concentration measurement cannot be interpreted apart from the genetic architecture, comparator, animal line, and downstream assay. The result is strong proof of concept for one promoter–locus design, but it does not by itself establish equivalent performance across therapeutic proteins or production settings.
Can CSN2 Knock-In Raise Rabbit Pharming Yield?
2026-11-18
A targeted rabbit line using endogenous CSN2 regulatory control produced unusually high reporter-protein concentrations in milk, but the evidence is based on a small number of animals and historical comparisons. The findings support a promising expression strategy, not yet a general conclusion about therapeutic-protein quality, scalability, or manufacturing performance.
A Native Milk Promoter for Rabbit Pharming
2026-11-18
A literature-focused analysis of a CRISPR/Cas9 rabbit line designed to express recombinant protein from the endogenous CSN2 milk-protein locus, emphasizing the reported yield, mechanistic rationale, comparison with historical pharming results, and limits on generalization.
How CSN2 Targeting Raises Rabbit Pharming Yield
2026-11-17
Targeting a transgene to the endogenous CSN2 milk-protein locus produced substantially higher reported expression than historical random-integration approaches, while leaving important questions about protein generalizability, animal-to-animal variation, and therapeutic product quality unresolved.
When Context Changes What a Research Result Means
2026-11-17
A reported protein concentration is not a context-free measure of performance. The rabbit pharming study illustrates how promoter choice, genotype, reporter identity, comparator selection, and assay definition determine whether a high value supports a mechanism, a proof of concept, or a broader production claim.
What the Degarelix Isotope Study Shows
2026-11-16
A literature-focused analysis of how deuterium-labeled degarelix was designed as an analytical internal standard, what the reported isotopologue and yield data establish, and why those findings should not be conflated with acetoacetate biology.
Why CSN2 Targeting Raised Rabbit Pharming Yield
2026-11-16
A 2025 study used a targeted CSN2-locus strategy to place a fluorescent reporter under the control of a native milk-protein promoter. The resulting homozygous rabbits produced 15–20 g/L of tdTomato in milk, a striking increase over many historically reported rabbit pharming lines. The result supports the value of coordinated locus and promoter selection, while leaving important questions about protein-specific behavior, product quality, population-level reproducibility and translational scalability.
When Context Changes What a Result Means
2026-11-15
A context-first analysis of how genotype verification, disease modeling, cellular readouts, and translational observations shape interpretation of the IRP2–lysosome findings, while distinguishing the role of the Mouse Tissue Lysis Kit K1038 from the biological evidence.
Why the CSN2 Locus Changed Rabbit Pharming
2026-11-14
A 2025 rabbit study links targeted insertion at the endogenous CSN2 locus with markedly higher reporter-protein concentrations in milk. The findings support a regulatory-locus mechanism, while leaving important questions about protein quality, reproducibility, animal physiology, and therapeutic applicability.
Why CSN2 Targeting Matters in Rabbit Pharming
2026-11-13
A literature-focused analysis of how endogenous CSN2 regulation, targeted insertion, and germline transmission supported unusually high tdTomato levels in rabbit milk, while highlighting the study’s comparator limitations and uncertain generalizability to therapeutic proteins.